首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷 CT/MRI/X光

市場調查報告書

商品編碼

2126688

PET成像試劑市場：按類型、應用、最終用戶和地區分類。

PET Imaging Agents Market, By Type, By Application, By End User, By Geography

出版日期: 2026年08月20日 | 出版商:

Coherent Market Insights | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，PET 成像試劑市場規模將達到 32.364 億美元，到 2033 年將達到 65.295 億美元。預計從 2026 年到 2033 年，該市場將以 10.5% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	32.364億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	10.50%	2033年市場規模預測：	65.295億美元

正子斷層掃描（PET）造影劑（放射性示蹤劑或放射性藥物）是標記有正子發射放射性核素的特定化合物，能夠以非侵入性方式在分子層面上可視化代謝和生理過程。 PET造影劑廣泛應用於腫瘤學、神經病學和循環系統領域。關鍵試劑包括氟代脫氧葡萄糖（FDG）、氟貝他吡啶和氟替卡松，以及用於疾病檢測和表徵的新型澱粉樣蛋白和Tau蛋白靶向示蹤劑。

隨著放射化學技術的進步、癌症和神經系統疾病負擔的加重以及分子影像技術的普及，涵蓋PET成像試劑的研發、生產和分銷的全球市場持續成長。此外，精準醫療和個人化診斷的日益普及也拓展了PET成像試劑在臨床決策中的作用，為製藥公司、研究機構和醫療服務提供者創造了新的機會。

市場動態

全球PET成像試劑市場成長的主要促進因素包括癌症和神經退化性疾病負擔的加重、對精準疾病檢測日益成長的需求，以及放射性示蹤劑在腫瘤學和神經病學領域臨床應用的不斷擴展。此外，新PET試劑的法規核准、核醫基礎設施的投資，以及PET/CT和PET/MRI技術的日益普及（這些都提高了診斷能力和臨床應用範圍），也促進了市場成長。

然而，市場仍存在諸多限制因素。例如，放射性核種半衰期短，對生產、運輸和供應鏈帶來挑戰；放射性藥物、迴旋加速器設施和PET掃描儀的高成本限制了其在資源匱乏地區的應用。儘管如此，包括前列腺特異性膜抗原（PSMA）和纖維母細胞激活蛋白抑製劑（FAPI）在內的新一代靶向示踪劑，以及診療一體化治療診斷學的日益普及和亞太、拉丁美洲和中東地區核醫學基礎設施的建設，有望為全球PET成像試劑市場創造新的機遇。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球 PET 成像試劑市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球PET影像診斷市場報告」旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球 PET 成像試劑市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

公司簡介
- Siemens Healthineers AG
- GE HealthCare Technologies Inc.
- Lantheus Holdings, Inc.
- Cardinal Health, Inc.
- Curium
- Bracco SpA
- Bayer AG
- Telix Pharmaceuticals Limited
- Eckert & Ziegler SE
- Jubilant Pharmova Limited

第9章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第10章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9969

PET Imaging Agents Market is estimated to be valued at USD 3,236.4 Mn in 2026 and is expected to reach USD 6,529.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3,236.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.50%	2033 Value Projection:	USD 6,529.5 Mn

Positron emission tomography (PET) imaging agents (radiotracers or radiopharmaceuticals) are specific chemical compounds labeled with positron-emitting radionuclides that permit non-invasive visualization of metabolic and physiological processes at the molecular scale. PET imaging agents are widely used in oncology, neurology, and cardiology. Major agents include Fluorodeoxyglucose (FDG), Florbetapir, and Flutemetamol, as well as novel amyloid- and tau-targeting tracers, for detection and characterization of diseases.

The global market for PET imaging agents includes the development, production, and distribution of these compounds and is growing as a consequence of advances in radiochemistry, the increasing burden of cancer and neurological disorders, and improved access to molecular imaging. The increasing adoption of precision medicine and personalized diagnostics is also increasing the role of PET imaging agents in clinical decision-making and providing opportunities for pharmaceutical companies, research organizations and healthcare providers.

Market Dynamics

The global PET imaging agents market is driven by the increasing burden of cancer and neurodegenerative disorders, rising demand for accurate detection of disease, and growing clinical application of oncology and neurological radiotracers. The market is also growing due to regulatory approvals of novel PET agents, investments in infrastructure of nuclear medicine, and increasing adoption of PET/Computed Tomography and PET/Magnetic Resonance Imaging, which are improving diagnostic capabilities and clinical applications.

However, a number of constraints are present in the market, such as short radionuclide half-lives pose challenges in terms of production, transportation and supply-chain, while high costs of radiopharmaceutical manufacturing, cyclotron facilities and PET scanners limit access in resource-constrained regions. Nevertheless, next-generation targeted tracers, including prostate-specific membrane antigen and fibroblast activation protein inhibitor agents, alongside the increasing use of theranostics and expansion of nuclear medicine infrastructure across Asia-Pacific, Latin America and the Middle East will offer opportunities within global PET imaging agents market.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global PET imaging agents market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Siemens Healthineers AG, GE HealthCare Technologies Inc., Lantheus Holdings, Inc., Cardinal Health, Inc., Curium, Bracco S.p.A., Bayer AG, Telix Pharmaceuticals Limited, Eckert & Ziegler SE, and Jubilant Pharmova Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global PET imaging agents market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PET imaging agents market

Market Segmentation

Type Insights (Revenue, USD Mn, 2021 - 2033)
Fluorine-18
Nitrogen-13
Gallium-68
Carbon-11
Others
Application Insights (Revenue, USD Mn, 2021 - 2033)
Cardiology
Oncology
Neurology
Others
End User Insights (Revenue, USD Mn, 2021 - 2033)
Hospitals
Diagnostic Imaging Centers
Specialty Clinics
Research Institutes
Others
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Siemens Healthineers AG
GE HealthCare Technologies Inc.
Lantheus Holdings, Inc.
Cardinal Health, Inc.
Curium
Bracco S.p.A.
Bayer AG
Telix Pharmaceuticals Limited
Eckert & Ziegler SE
Jubilant Pharmova Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global PET Imaging Agents Market, By Type
- Global PET Imaging Agents Market, By Application
- Global PET Imaging Agents Market, By End User
- Global PET Imaging Agents Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Industry Trends

4. Global PET Imaging Agents Market, By Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Fluorine-18
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Nitrogen-13
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Gallium-68
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Carbon-11
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global PET Imaging Agents Market, By Application, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cardiology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global PET Imaging Agents Market, By End User, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Diagnostic Imaging Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global PET Imaging Agents Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Company Profile
- Siemens Healthineers AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GE HealthCare Technologies Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Lantheus Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Cardinal Health, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Curium
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bracco S.p.A.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Telix Pharmaceuticals Limited
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eckert & Ziegler SE
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Jubilant Pharmova Limited
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies